Fig 1.
ROI placement and Ktrans analysis.
Example of ROI placement in a lung tumor of the left upper lobe (left) and derived time curve of contrast agent enhancement (right) using the PulmoMR software (Mevis Fraunhofer, Bremen, Germany).
Table 1.
Patient number and lesion characteristics.
Fig 2.
Example of Ktrans decrease during therapy.
NSCLC of the left upper lobe showing a clear decrease of Ktrans from baseline (left) to first follow-up after 1 week of checkpoint inhibition by Erlotinib and Bevacizumab.
Fig 3.
Distribution of Ktrans values.
Boxplot showing the median, the 25th and 75th percentiles respectively the 1.5 interquartile range below the 25th and above the 75th percentile of Ktrans (min-1) during therapy with Erlotinib and Bevacizumab.
Table 2.
Ktrans values.
Fig 4.
Percentual change of Ktrans and tumor size in minor and major responders during therapy with Erlotinib and Bevacizumab.
Table 3.
Interrater reliability.
Table 4.
Intrarater agreement.